Fasidotril is primarily investigated for its potential therapeutic applications in cardiovascular diseases. It functions as a dual inhibitor of both neutral endopeptidase (NEP) and angiotensin-converting enzyme (ACE), which makes it effective in regulating blood pressure and fluid balance. By inhibiting these enzymes, Fasidotril helps in the reduction of hypertension and can be beneficial in the treatment of heart failure. Its dual action promotes vasodilation and decreases sodium retention, contributing to improved cardiac function and reduced strain on the heart. Research continues to explore its efficacy and safety in clinical settings for managing these conditions.